验证人类诱导的多能干细胞特异性质量控制试验,用于在良好的制造实践质量体系中释放中间药物产品
Juan Novoa1, Inge Westra2, Esther Steeneveld1
1Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Cytotherapy
|May 4, 2024
概括
这项研究验证了符合良好制造实践 (GMP) 的人类诱导多能干细胞 (hiPSC) 的质量控制试验. 经过验证的测试确保了用于临床应用的hiPSC的安全性和质量.
科学领域:
- 干细胞生物学 干细胞生物学
- 生物技术是生物技术.
- 质量控制 质量控制 质量控制
背景情况:
- 在良好的制造实践 (GMP) 下生产人类诱导的多能干细胞 (hiPSC) 需要对批量释放进行验证的质量控制 (QC) 测试.
- 目前面临的挑战包括对hiPSC进行特定QC测定验证,确保它们适用于临床应用.
研究的目的:
- 为了全面描述符合GMP的QC测定对hiPSCs特定的验证过程.
- 验证检测残留病例载体 (REV) 的测试,确认多能性标记物,并评估定向差异化潜力.
主要方法:
- 试验验证包括测试特异性,灵敏性和可重复性,根据预先定义的验证计划,并具有特定的接受标准.
- 对于每个测试,设备的性能资格进行了评估.
- 定义了REV检测的最小细胞输入和REV的推查通道8-10由于通道依赖向量损失而导致的REV.
主要成果:
- 确立了REV检测,多能标志物表达 (≥75%的细胞上≥3个标志物) 和定向分化潜力 (每种生殖层≥2个血统标志物) 的具体标准.
- 推的光减去一个对多色流细胞计板的控制.
- 所有经过验证的试验都显示出可重复性和特异性.
结论:
- 实施的分析程序适用于高质量检测测试验和hiPSCs的GMP批量释放.
- 这种验证过程确保了治疗用途的hiPSC的质量和安全性.
相关概念视频
01:10In Vitro Drug Release Testing: Overview, Development and Validation
566
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
566
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
285
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
285